Table 1.
Patients’ Characteristics.
| Patient characteristics | TA-TMA (n = 20) | GVHD (n = 20) | Controls (n = 20) | P |
|---|---|---|---|---|
| Age (y) | 36 (17-56) | 42 (19-52) | 39 (18-49) | 0.212 |
| Disease type (n) | ||||
| AML | 4 | 5 | 6 | 0.228 |
| ALL | 12 | 9 | 10 | |
| Lymphoma | 3 | 5 | 3 | |
| Multiple myeloma | 1 | 1 | 1 | |
| Disease phase (n) | ||||
| Early CR | 12 | 14 | 13 | 0.421 |
| Late CR | 4 | 3 | 4 | |
| Relapsed/Refractory | 4 | 3 | 3 | |
| Myeloablative conditioning (n) | 16 | 8 | 16 | 0.892 |
| Donor (n) | ||||
| Sibling | 8 | 10 | 9 | 0.732 |
| Unrelated | 8 | 5 | 6 | |
| Haploidentical | 4 | 5 | 4 | |
| HLA matched donor (n) | 16 | 17 | 18 | 0.343 |
| Follow-up (mo) | 8.5 (2.7-102.1) | 12.0 (2.9-32.2) | 14.2 (4.5-79.1) | 0.745 |
| Infections (n) | ||||
| Bacterial | 12 | 12 | 10 | 0.431 |
| Viral | 13 | 11 | 9 | 0.373 |
| Fungal | 10 | 7 | 12 | 0.653 |
| GVHD (n) | ||||
| Severe acute | 12 | 18 | 0 | <0.001 |
| Extensive chronic | 17 | 19 | 0 | <0.001 |
| EASIX at day 0 | 1.57 (0.3-18.9) | 1.37 (0.3-4.4) | 1.4 (0.2-6.2) | 0.565 |
| Platelets (×103/L) at day 0 | 52 (16-198) | 80 (21-145) | 62 (10-183) | 0.528 |
| LDH (mg/dL) at day 0 | 169 (113-445) | 178 (94-365) | 161 (91-211) | 0.639 |
| Creatinine (mg/dL) at day 0 | 0.72 (0.32-0.93) | 0.60 (0.33-0.98) | 0.49 (0.24-0.94) | 0.465 |
| EASIX at day 30 | 2.5 (0.8-16.3) | 1.9 (0.1-8.5) | 1.4 (0.4-8.5) | 0.091 |
| Platelets (×103/L) at day 30 | 107 (10-167) | 99 (31-262) | 135 (54-203) | 0.462 |
| LDH (mg/dL) at day 30 | 278 (144-465) | 257 (161-698) | 264 (151-698) | 0.887 |
| Creatinine (mg/dL) at day 30 | 0.93 (0.32-2.20) | 0.82 (0.42-1.50) | 0.71 (0.47-1.29) | 0.225 |
| EASIX at day 100 | 7.2 (1.1-118.2) | 3.3 (1.8-12.1) | 1.41 (0.2-30.8) | 0.014 |
| Platelets (×103/L) at day 100 | 55 (8-168) | 61 (29-247) | 127 (21-226) | 0.012 |
| LDH (mg/dL) at day 100 | 330 (152-679) | 261 (135-666) | 203 (113-564) | 0.425 |
| Creatinine (mg/dL) at day 100 | 0.83 (0.41-2.5) | 0.77 (1.22-2.34) | 0.65 (0.36-0.89) | 0.187 |
| EASIX at last follow-up | 22.7 (0.3-604.3) | 7.8 (0.6-210.1) | 0.89 (0.1-62.7) | 0.001 |
| Platelets (×103/L) at last follow-up | 44 (2-359) | 70 (14-270) | 154 (90-171) | 0.002 |
| LDH (mg/dL) at last follow-up | 593 (182-1515) | 455 (153-1815) | 199 (133-421) | 0.001 |
| Creatinine (mg/dL) at last follow-up | 0.95 (0.41-4.82) | 1.04 (0.62-4.17) | 0.75 (0.49-1.43) | 0.074 |
| Soluble C5b-9 (ng/mL) | 325 (184-902) | 243 (175-454) | 227 (53-281) | 0.001 |
Continuous variables are presented as median (range). The P value represents differences between the three groups, performed with the χ2 test for categorical and Kruskal-Wallis test for continuous variables.
ALL = acute lymphocytic leukemia, AML = acute myeloid leukemia, CR = complete remission, EASIX = Endothelial Activation and Stress Index, GVHD = graft-versus-host-disease, HLA = human leukocyte antigen, LDH = lactate dehydrogenase, TA-TMA = transplant-associated thrombotic microangiopathy.